Tucatinib (Tukysa) in combination with trastuzumab (Herceptin) and capecitabine yielded significant intracranial responses in patients with previously treated HER2-positive metastatic breast cancer and brain metastases, according to findings from a subset of patients in the HER2CLIMB trial presented in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.1
“Tucatinib is the first tyrosine kinase inhibitor to demonstrate prolongation of overall survival in patients with HER2-positive metastatic breast cancer with brain metastases in a randomized, controlled trial,” said investigator Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, and director, Metastatic Breast Cancer Program, Dana-Farber Cancer Institute in Boston, Massachusetts.
A report of findings from the subset of patients with brain…
